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Hereditary  angioedema  (HAE)  is  a  disease  characterized  clinically  by recurrent 
episodes of swelling in the tissues of the extremities, face, abdomen, and respiratory 
tract, and hiochemically by a deficiency ofC 1 inhibitor function, usually in association 
with an absence of C1  inhibitor protein  (1-5).  In studies of HAE, Landerman et al. 
(6) demonstrated the deficiency of a serum inhibitor of kallikrein, and postulated that 
unregulated  kallikrein  activity in  tissue interstitial  fluids was the etiologic agent  in 
HAE. Subsequent studies revealed that C 1 inhibitor is the deficient serum inhibitory 
protein in HAE and also established it as a  major inactivator of kallikrein  (4,  7).  In 
addition  to kallikrein  inactivation,  further  investigations  of C1  inhibitor showed  it 
also could inactivate activated Hageman factor, factor XIa, plasmin, Clr,  and C l s 
(8-13). Thus C 1 inhibitor is multifunctional and acts as a primary regulatory protein 
in both the Hageman-factor-dependent pathways (contact system) and in the classical 
pathway of complement. 
As yet, the etiologic role(s) for either or both of these pathways in the pathogenesis 
of HAE is not clearly established. Studies by Donaldson and Evans (13), Austen and 
Sheffer  (14),and  Pitts  et  al.  (15)  showed  that  plasmas  from  HAE  patients  often 
contained C 1, the activated first component of complement, and low levels of C4 and 
C2,  indicative  of the  unregulated  cleavage of these  substrate  proteins  by the Cls 
subunit of CT. In vitro experiments showed that mixtures ofC  ls, C4, C2, and plasmin 
produced  a  kinin-like activity  (C2 kinin)  similar to the kinin  activity isolated  from 
plasmas of patients who experience acute HAE attacks  (16,  17). This C2-kinin  was 
postulated to be the mediator of HAE. 
Because C 1 inhibitor is a major regulatory protein in the Hageman-factor-depend- 
ent  pathways and  because plasmin was required  for the  in  vitro generation  of C2- 
kinin, one anticipates activation of the contact system in HAE. To assess activation 
of the Hageman-factor-dependent pathways in the interstitial  fluids from the sites of 
traumatic swelling,  we have induced  suction  blisters on these sites  in  patients with 
HAE and in normal volunteers. We found that the blister fluid obtained from HAE 
patients contained large amounts of active kallikrein that was inhibitable by purified 
C1  inhibitor  or by antibodies  specific for plasma prekallikrein.  These observations 
suggest that trauma initiates activation of the Hageman-factor-dependent pathways 
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in  the  tissues  of HAE  patients  and  produces  kallikrein activity.  Furthermore,  this 
kallikrein activity persists and is unregulated in these damaged tissues. 
Materials  and  Methods 
Subjects and Study Protocol.  The  patients with  HAE  who  volunteered  for  the  study were 
patients receiving their medical care at the Clinical Research Center (CRC) of Scripps Clinic 
and  Research  Foundation,  La Jolla, Calif.  The  normal  volunteers  were  selected from  the 
employees of this institution. The age, sex, medical treatment, clinical symptoms, and plasma 
C1  inhibitor levels at  the time of the study are shown  in Table I. The study protocol was 
approved by the Human Research Committee of the Scripps Clinic and Research Foundation 
and  consisted  of admission to  the  CRC,  solicitation of informed  consent,  precipitation of 
localized swelling on the forearm by traumatic vibration for  10 rain with an inverted vortex 
Genie mixer (Scientific Products Div., American Hospital Supply Corp., McGaw Park, I11.) 
and immediate induction of a suction blister. The suction blisters were induced on the vibrated 
forearm with  the apparatus described by Kiistala (18)  and  modified by Kaplan et  al.  (19) 
(John  Markle  Specialty Parts,  San  Diego, Calif.). The  temperature  in  the  apparatus  was 
maintained between 48  and  51°C  for 30-60  min  with  a  suction of 200  mm  mercury. The 
blisters were then aspirated, and the fluids (~0.2-0.5 ml) stored in plastic tubes at -70°C until 
analysis. 
Studies of Blister Fluids.  The total protein concentration of each blister fluid was estimated 
with the Folin reagent by comparison with bovine albumin standard solutions. The presence of 
the following proteins was qualitatively ascertained by double immunodiffusion against mon- 
ospecific antisera in  1% agarose (Seakem; Marine Colloids, Inc., Rockland, Maine) gels that 
contained  0.01  M  veronai-buffered saline,  pH  8.6,  and  0.02  M  EDTA:  Hageman  factor, 
prekallikrein, high molecular weight kininogen (HMWK), plasminogen, C l s, C 1 inhibitor, a2- 
macroglobulin, oq-anti-trypsin, anti-thrombin  III, inter a-trypsin inhibitor, a2-anti-plasmin, 
and  anti-chymotrypsin. Sodium  dodecyl sulfate  (SDS)  polyacrylamide (9%) slab  gels were 
•  125  prepared according to  Laemmli  (20)  and  used  to  detect enzymes capable of cleaving  1- 
125  125  125  Hageman factor,  I-prekallikrein  I-HMWK, and  I-plasminogen. 5/tl of each blister fluid 
was incubated with of each radiolabeled protein at 37°C for 45 rain. After electrophoresis, the 
distribution  of radioactivity in  the  gel  was  determined  by  autoradiography  of the  dried 
Coomassie-blue-R250-stained gel. Inhibition of the cleavage of HMWK by the blister fluid was 
accomplished by  preincubation  of the  diluted blister fluid  (1/20)  with  either  purified  C1 
inhibitor (90 #g/ml final concentration) or with goat antibodies (1 mg/ml final concentration) 
to  prekailikrein isolated from  a  prekallikrein-Sepharose affinity column•  The  ability of the 
blister  fluids  to  cleave  HMWK  and  release  bradykinin  from  5  #g  purified  HMWK  was 
measured with the estrus rat uterus in a  3-ml bath that contained de Jalon's solution. The 
latent period between the time of addition and the onset of contraction was employed to assess 
the activity. The quantity of kinin present was estimated from a standard curve generated with 
synthetic bradykinin (Sandoz Pharmaceuticals, Hanover, N. J). A  final concentration of 1 × 
10  -3 M  1,10-phenanthroline and SQ 20881  (E. R. Squibb and Sons, New York), an inhibitor 
of angiotensin-convcrting enzyme,  was  added  to  the  blister fluids  before  incubation  with 
HMWK to prevent inactivation of the generated bradykinin. The Hageman factor, prekalli- 
krein, HMWK, and plasminogen employed in these studies were purified from normal human 
plasma and were homogeneous as judged by SDS-polyacrylamide gel electrophoresis (SDS- 
PAGE), immunoelectrophoresis, and double immunodiffusion (21-23). The purified Hageman 
factor and prekallikrein reconstituted the functional clotting activities of plasmas that  were 
genetically deficient in these proteins. All proteins were radiolabeled with 125I by the chloramine 
T  method (24).  Kallikrein was prepared from prekallikrein by incubation with trace amounts 
of activated Hageman factor. 
Results 
We obtained six blister fluids from five patients with HAE and eight blister fluids 
from eight normal volunteers. The blister fluids were assayed immunochemically for 744  CURD ET AL.  BRIEF  DEFINITIVE REPORT 
TAnLE I 
Characteristics of Subjects Who Volunteered  for Induction of Suction Bhsters 
C1  inhibi- 
Subject  Diagnosis  Age  Sex  Medications  Symptoms  tor level 
)7 
[ C.W.  HAE  50  F  None  16 attacks/too  28 
2 P.M.  HAE  27  F  Stanozolol  3 attacks/too  46 
3 V.C.  HAE  13  F  Stanozolol  1 attack/too  27 
4 S.M.  HAE  51  F  Danocrine  None  54 
5a J.L.  HAE  60  M  Danocrine  daily swelling  72 
5b J.L.  HAE  60  M  None fi)r {i d  daily' swelling  58 
HAE indicates established diagnosis  of HAE. All HAE patients exhibited clinical  symptoms of HAE and deficiency  of Cl 
inhibitor function and protein. Patient J.L. has no family history' of angioedenta. The normal subjects  studied included 
five males and three females ranging in age from 28 to 40 yr.  Plasma levels of CI  inhibitnr were determined by radial 
immunodiffusion and are given as pg/ml with a normal range being 145  227 ffg/nd.  Plasma front all normal individuals 
contained apparently normal concentrations of CI  inhibitor as determined by double diffusion  innnunoprecipitation 
techniques. 
Hageman factor, prekallikrein, HMWK, plasminogen, C ls, C1  inhibitor, a2-macro- 
globulin, al-anti-trypsin, and al-anti-chymotrypsin. All blister fluids analyzed con- 
tained detectable amounts of all of the proteins except C 1 inhibitor. The blister fluids 
from the patients with HAE exhibited qualitatively less HMWK and C1  inhibitor 
than those obtained from the normal volunteers. 
Because the patients with HAE had low levels of C1  inhibitor in  their plasmas 
(Table  I), we questioned whether the blister fluids might contain active Hageman 
factor and/or kallikrein, two of the proteases inactivated by C 1 inhibitor. Studies of 
the  HAE  blister fluids showed that  all six  fluids from the  five patients contained 
kallikrein-like activity capable  of cleaving radioiodinated  HMWK  (125I-HMWK), 
whereas only two of eight blister fluids obtained from normal volunteers contained 
any detectable amount of this activity (Fig.  1).  The  HAE blister fluids contained 
more l~SI-HMWK-cleaving activity than the two normal blister fluids that contained 
this activity. None of the blister fluids from either the HAE patients or the normal 
volunteers contained enzymes that cleaved radioiodinated Hageman factor, prekalli- 
krein, or plasminogen under  the conditions of the experiment.  The  kallikrein-like 
activity in  HAE  blister  fluids cleaved  125I-HMWK  into  fragments similar  to  the 
fragments  of I~SI-HMWK produced  by  incubation  with  purified  human  plasma 
kallikrein (Figs.  1 and 2). The HMWK cleaving activity in HAE blister fluids and 
purified  human  kallikrein were  both  completely inhibited  by  preineubation  with 
excess  purified C1  inhibitor  (Fig.  2).  Preincubation of the HAE blister fluids and 
isolated human kallikrein with immunopurified goat antibodies specific for human 
prekallikrein also produced marked inhibition of the cleavage of 125I-HMWK (Fig. 2). 
Preincubation of HAE blister fluids and kallikrein with goat antibodies specific for 
Cls (2 mg/ml final concentration) did not inhibit the cleavage of 12~I-HMWK (data 
not shown). 
Because the enzymatic digestion of HMWK by kallikrein produces bradykinin, we 
studied  the  abilities  of HAE  blister  fluids  to  generate  smooth-muscle-contracting 
activity during incubation with purified HMWK. Four HAE blister fluids generated 
kinin activity as assayed on rat  uterus, whereas none of three normal blister fluids 
produced kinin (Table II). Comparison of the kinin activity produced by the HAE 
blister  fluids with  the  kinin  activity produced  by  purified  kallikrein and  purified 
HMWK indicates that four HAE blister fluids contained large amounts of kallikrein- 
like  activity  (Table  II).  The  smooth-muscle-contracting  substance  released  from CURD  ET  AL.  BRIEF  DEFINITIVE  REPORT  745 
Fic.  1.  Representative autoradiogram of SDS-PAGE demonstrating cleavage of ~z'~I-HMWK by 
blister fluids obtained from patients with HAE. Kallikrein preparation utilized in lane on right side 
of SDS-PAGE was different from preparation utilized on left. NL, normal control. 
FIG.  2.  Autoradiogram of SDS-PAGE demonstrating cleavage of '25I-HMWK by blister fluid and 
purified kallikrein and inhibition of cleavage by purified C 1 inhibitor or anti-prekallikrein antibod- 
ies. CI  INH, CI  inhibitor; ANTI-PK, anti-prekallikrein. 
TABLE  II 
Determinations of Kinin-releasing Activities in Blister Fluids 
Subject  Kinin released 
ng 
HAE patients 
1 C.W.  21.9 
3 V.C.  6.4 
4 S.M.  5.2 
5a J.L.  26.0 
5b J.L.  0 
Kallikrein  (650 ng)  38.4 
The quantity of kinin was obtained by comparison  of the contraction  of the estrus rat 
uterus with that obtained using  synthetic bradykinin.  The blister fluids frum three normal 
subjects contained no detectable  amounts of released kinin. 
HMWK by HAE blister fluids or by kallikrein was abrogated by preincubation with 
chymotrypsin  (10  /xg). Both  of the  normal  blister  fluids  that  had  cleaved  small 
amounts of 125I-HMWK were included in the three normal blister fluids studied with 
the kinin-generating assay and neither generated detectable smooth-muscle-contract- 
ing activity. 
Discussion 
The primary observation of these studies is that the suction blister fluids obtained 
from patients with HAE contained large amounts of active kallikrein, whereas similar 
blister fluids obtained from normal individuals did not. The kallikrein activity present 746  CURD  ET  AL.  BRIEF  DEFINITIVE REPORT 
in HAE blister fluids appeared similar to plasma kallikrein in that it cleaved HMWK, 
released kinin  from purified HMWK,  and  was  inhibited  by antibodies specific for 
plasma  prekallikrein. The kallikrein activity was also abolished by incubation with 
C1  inhibitor, but not by antibodies specific to Cls. The concentrations of kallikrein 
activity  in  some  blister  fluids  approached  the  concentration  of total  activatable 
kallikrein in human plasma  (50/~g/ml), although the estimates of kallikrein activity 
in HAE blister fluids varied from 10 to 44/xg/ml. These observations suggest activation 
of the  Hageman-factor-dependent  pathways  with  generation  of plasma  kallikrein 
during the induction of blisters.  However, the activation of a  tissue kallikrein that 
bears antigenic cross-reactivities with plasma kallikrein has not been excluded. The 
persistence of kallikrein activity in blister fluids appears to result from the lack of C 1 
inhibitor in the blister fluid. The decreased levels of C 1 inhibitor in the blister fluids 
from HAE patients probably reflects the low plasma levels of this protein. One HAE 
blister fluid (5b J.L.) contained only small amounts of kallikrein activity and did not 
release kinin from HMWK. This result was unexpected because another blister fluid 
obtained from this patient during Danocrine treatment did contain large amounts of 
kallikrein. The reasons for these differences are not clear. 
The presence of kallikrein in HAE blister fluids indicates that activation within the 
Hageman-factor-dependent pathways can occur in the tissues of these patients. These 
studies do not distinguish among the putative inflammatory mediators that may be 
responsible for the pathophysiological features of HAE. However, they do suggest that 
the Hageman-factor-dependent pathways or, possibly, a  tissue kallikrein may play a 
role in this disease, either by production of bradykinin from HMWK, by activation 
of plasmin  in  situ,  or by some other yet  undefined mechanism.  Further studies  of 
blister  fluids obtained  from patients  with  HAE  may provide new  insight  into the 
pathogenesis of HAE. 
Summary 
Six  suction-induced  blister  fluids  obtained  from  five  patients  with  hereditary 
angioedema  (HAE)  contained active kallikrein, whereas only two blister fluids ob- 
tained from eight normal volunteers contained small amounts of this activity. Kallik- 
rein was present in large amounts of HAE blister fluids as assessed by its ability to 
liberate  smooth-muscle-contracting  activity  from  purified  high  molecular  weight 
kininogen.  It was  inhibited by purified antibodies specific for plasma  prekallikrein 
and  also  by  purified  C1  inhibitor,  but  not  by  antibodies specific  for Cls.  These 
observations  suggest  that  activation  of the  Hageman-factor-dependent  pathways 
occurs in the tissues of HAE patients, and once generated, active kallikrein persists in 
these tissues. 
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